Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 359–360 (1 April 2008) | doi:10.1038/nbt0408-359
US credit crunch impacts biotech across the globe
Abstract
The worldwide shortage of debt finance triggered by the US property slump is touching vast corners of the global economy, and venture capitalists expect it will depress biotech company valuations even further this year. It also remains to be seen whether the credit crunch will be coupled with reduced investment volumes.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
